	US 12,268,704 B2
	Hippo regulation of cardiac vascularity, fibrosis, and inflammation
James F. Martin, Houston, TX (US)
Assigned to Baylor College of Medicine, Houston, TX (US)
Appl. No. 17/049,891
Filed by Baylor College of Medicine, Houston, TX (US)
PCT Filed Apr. 23, 2019, PCT No. PCT/US2019/028777 § 371(c)(1), (2) Date Oct. 22, 2020, PCT Pub. No. WO2019/209865, PCT Pub. Date Oct. 31, 2019.
Claims priority of provisional application 62/661,325, filed on Apr. 23, 2018.
Prior Publication US 2021/0322454 A1, Oct. 21, 2021
Int. Cl. A61K 31/713 (2006.01); A61P 9/10 (2006.01); C12N 15/63 (2006.01); C12N 15/86 (2006.01); C12Q 1/68 (2018.01)

CPC A61K 31/713 (2013.01) [A61P 9/10 (2018.01); C12N 15/63 (2013.01); C12N 15/86 (2013.01)]

11 Claims

1. A method of inhibiting fibrosis and/or inflammation in cardiac tissue, the method comprising the step of contacting cardiac fibroblasts in the cardiac tissue with an agent that increases the level of at least one of Large tumor suppressor kinase 1 (LATS1) or Large tumor suppressor kinase 2 (LATS2) in the cardiac tissue;

wherein the agent that increases the level of LATS1 is a LATS1 polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 2 or a nucleic acid encoding the LATSI polypeptide; and

wherein the agent that increases the level of LATS2 is a LATS2 polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 4 or a nucleic acid encoding the LATS2 polypeptide.